journal article·2024-03-19

Nanocarriers for the Delivery of Quercetin to Inhibit the UV-Induced Aggregation of γD-Crystallin

Vishakha Goswami, Vijay Raj Tomar, Yashika, Shashank Deep

Langmuir· Volume 40· Issue 11
Publisher page

Abstract

Due to gradual environmental changes like ozone layer depletion and global warming, human eyes are exposed to UV light. Exposure to UV light can be a cause of cataracts, one of the ocular diseases that may cause vision impairment. To date, lens replacement has been the only treatment available for cataracts. In our present study, we carried out an extensive examination of polyphenols as inhibitors for UV-induced aggregation of γD-crystallin. On exposure to UV-C light, γD-crystallin forms fibrils instead of amorphous aggregates. Various polyphenols were tested as inhibitors; out of them, quercetin, baicalein, and caffeic acid were found to be effective. As polyphenols are insoluble in water, nanoencapsulation was used to enhance their bioavailability. CS-TPP and CS-PLGA encapsulating systems were considered, as they form biodegradable nanocapsules. Out of three polyphenols (quercetin, baicalein, and caffeic acid), quercetin forms nanocarriers of smaller sizes, a must for crossing the retinal barrier. Quercetin nanocarriers were considered an effective system that could be used for therapeutic applications. For these nanocarriers, encapsulation efficiency and polyphenol release kinetics were studied. CS-PLGA NPs were found to have a better loading efficiency for quercetin than CS-TPP NPs.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Glycation End Products research · Biochemical effects in animals · Connexins and lens biology

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Chemistry, Indian Institute of Technology, Hauzkhas, Delhi New Delhi 110016, India

Funding

Department of Biotechnology, Ministry of Science and Technology, India · Indian Institute of Technology Delhi

References (56)

Show source-provided references
1. 10.1073/pnas.101915210810.1073/pnas.1019152108 ↗
2. ISO 21348. Information Is Provided Courtesy of Space Environment Technologies Spacenvironment@spacenvironment.Net Http://SpaceWx.Com. ISO 21348 Definitions of Solar Irradiance Spectral Categories Spectral Category Spectral Sub-Category. http://SpaceWx.com.
3. 10.1073/pnas.77.3.127410.1073/pnas.77.3.1274 ↗
4. 10.1016/j.exer.2004.12.00710.1016/j.exer.2004.12.007 ↗
5. 10.1167/iovs.03-055810.1167/iovs.03-0558 ↗
6. 10.1038/srep0156010.1038/srep01560 ↗
7. 10.1016/S1011-1344(01)00208-110.1016/S1011-1344(01)00208-1 ↗
8. 10.1021/bi400835310.1021/bi4008353 ↗
9. 10.1007/BF0022071110.1007/BF00220711 ↗
10. 10.1016/j.jmb.2017.04.01410.1016/j.jmb.2017.04.014 ↗
11. Bawankar M. · Mol. Vis · 2021 · 27 · 415
12. 10.1016/j.bpj.2010.12.369110.1016/j.bpj.2010.12.3691 ↗
13. 10.1016/j.saa.2021.12002310.1016/j.saa.2021.120023 ↗
14. 10.1021/acs.langmuir.2c0326310.1021/acs.langmuir.2c03263 ↗
15. 10.4103/0973-7847.7090210.4103/0973-7847.70902 ↗
16. 10.1016/j.jff.2015.06.01810.1016/j.jff.2015.06.018 ↗
17. 10.1016/S0531-5565(01)00139-510.1016/S0531-5565(01)00139-5 ↗
18. Shieh D. E. · Anticancer Res. · 2000 · 20 · 2861
19. 10.1155/2013/16275010.1155/2013/162750 ↗
20. 10.1016/S0031-6865(97)00021-610.1016/S0031-6865(97)00021-6 ↗
21. 10.1016/j.preteyeres.2010.08.00210.1016/j.preteyeres.2010.08.002 ↗
22. 10.1007/s40005-019-00439-x10.1007/s40005-019-00439-x ↗
23. 10.3390/polym303137710.3390/polym3031377 ↗
24. 10.3389/fphar.2018.0126010.3389/fphar.2018.01260 ↗
25. 10.1016/j.jcis.2018.03.00810.1016/j.jcis.2018.03.008 ↗
26. 10.2174/187419240080201006010.2174/1874192400802010060 ↗
27. 10.1081/DDC-12000299710.1081/DDC-120002997 ↗
28. 10.1016/j.ijpharm.2003.12.01810.1016/j.ijpharm.2003.12.018 ↗
29. Hartmann V. · Pharmazie · 2000 · 55 · 440
30. 10.1002/advs.20210537310.1002/advs.202105373 ↗
31. 10.1016/j.ijpharm.2007.06.01110.1016/j.ijpharm.2007.06.011 ↗
32. 10.3109/1071754090350900110.3109/10717540903509001 ↗
33. 10.1186/s13104-015-1618-610.1186/s13104-015-1618-6 ↗
34. 10.3390/molecules2704132610.3390/molecules27041326 ↗
35. 10.1016/j.bpj.2010.10.01010.1016/j.bpj.2010.10.010 ↗
36. 10.1039/C4CP05563B10.1039/C4CP05563B ↗
37. 10.1016/j.bbapap.2010.04.00110.1016/j.bbapap.2010.04.001 ↗
38. 10.1038/nprot.2006.20210.1038/nprot.2006.202 ↗
39. 10.1016/j.giant.2020.10002210.1016/j.giant.2020.100022 ↗
40. 10.1016/j.bcp.2017.04.00410.1016/j.bcp.2017.04.004 ↗
41. 10.3390/molecules2603066010.3390/molecules26030660 ↗
42. 10.3390/polym303137710.3390/polym3031377 ↗
43. 10.1016/j.plefa.2017.05.00110.1016/j.plefa.2017.05.001 ↗
44. 10.1016/j.actatropica.2013.07.01310.1016/j.actatropica.2013.07.013 ↗
45. Singh G. · Int. J. Pharmacol. Pharm. Sci. · 2014 · 1 · 30
46. 10.1208/s12249-013-9943-310.1208/s12249-013-9943-3 ↗
47. 10.1016/j.ultsonch.2021.10583010.1016/j.ultsonch.2021.105830 ↗
48. 10.1016/j.ijbiomac.2016.07.00210.1016/j.ijbiomac.2016.07.002 ↗
49. 10.1007/s13197-011-0251-110.1007/s13197-011-0251-1 ↗
50. 10.3390/molecules2713408410.3390/molecules27134084 ↗
51. 10.1021/jf202224j10.1021/jf202224j ↗
52. 10.1016/j.molliq.2022.12023610.1016/j.molliq.2022.120236 ↗
53. 10.1155/2018/861320910.1155/2018/8613209 ↗
54. 10.3390/biom1001005910.3390/biom10010059 ↗
55. 10.1021/acsomega.0c0181810.1021/acsomega.0c01818 ↗
56. 10.1155/2019/768305110.1155/2019/7683051 ↗